Table 5.
VE and VPDI for pneumococcal conjugate vaccine in trials measuring radiological pneumonia outcomes, by trial site
| Serotypes in vaccine (n) | Vaccine type invasive pneumococcal disease
|
All serotype invasive pneumococcal disease
|
Pneumonia with lobar radiological consolidation/pleural effusion18
|
Clinical pneumonia
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| VE (%) | VPDI* | VE (%) | VPDI* | VE (%) | VPDI* | VE (%) | VPDI* | ||
| California, USA19,22 | 7 | 94%† | 2.43 | 89%† | 2.58 | 28% | 1.55 | 7% | 3.30 |
|
| |||||||||
| South Africa15 (HIV negative) | 9 | 83%† | 0.75 | 42% | 0.43 | 20%† | 2.31 | 7% | 3.94 |
|
| |||||||||
| Navajo/White Mountain Apache, USA23 | 7 | 83%† | 1.92 | 52% | 0.77 | −11% | −3.97 | NA | N/A |
|
| |||||||||
| The Gambia12 | 9 | 71%† | 3.67 | 45%† | 3.78 | 35%† | 23.2 | 6%† | 15.4 |
|
| |||||||||
| Philippines24,25 | 11 | −199% | −0.33 | 0.4% | 0 | 16% | 3.62 | −1% | 2.05 |
VE=Vaccine effectiveness. VPDI=vaccine-preventable disease incidence. All results given are from intention-to-treat analysis for all enrolled children. Adapted from the Cochrane review of pneumococcal conjugate vaccines.24 VPDI is expressed per 1000 person-years of follow-up.
*
Denominators were number of children for California, USA; South Africa; The Gambia; and Philippines; and were person-years for Navajo/White Mountain Apache, USA.
†
VE has 95% CIs that exclude 0.